COHERUS BIOSCIENCES I

0.8200

07-November-24 14:59:58

15 minutes delayed

Stocks

+0.0962

+13.29%

Today's range

0.7610 - 0.9550

ISIN

N/A

Source

NASDAQ

Coherus BioSciences Announces New Employment Inducement Grants

23 Feb 2024 16:33:13 By Nasdaq GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

05 Feb 2024 07:00:01 By Nasdaq GlobeNewswire
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

22 Jan 2024 00:15:00 By Nasdaq GlobeNewswire
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

18 Jan 2024 15:05:00 By Nasdaq GlobeNewswire
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
Coherus Announces U.S. Launch of LOQTORZI™

02 Jan 2024 07:29:00 By Nasdaq GlobeNewswire
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

26 Dec 2023 15:01:00 By Nasdaq GlobeNewswire
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

11 Dec 2023 07:30:00 By Nasdaq GlobeNewswire
Coherus BioSciences Announces CFO Transition Plans

07 Dec 2023 16:55:48 By Nasdaq GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

06 Dec 2023 03:00:00 By Nasdaq GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

28 Nov 2023 10:16:23 By Nasdaq GlobeNewswire
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

06 Nov 2023 15:07:41 By Nasdaq GlobeNewswire
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

03 Nov 2023 07:30:00 By Nasdaq GlobeNewswire
Coherus BioSciences to Participate at Upcoming November Investor Conferences

02 Nov 2023 19:00:08 By Nasdaq GlobeNewswire
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

30 Oct 2023 17:00:00 By Nasdaq GlobeNewswire
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

27 Oct 2023 14:07:20 By Nasdaq GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants

24 Oct 2023 18:41:27 By Nasdaq GlobeNewswire
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

14 Oct 2023 11:30:00 By Nasdaq GlobeNewswire
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

05 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.